Clinical Trial

Phase II Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above

Name: Phase II Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above — clinical trial record (NCT07285278)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The primary objective of this study is to evaluate the immunogenicity and safety of 2 injections (approximately 2 months apart) of ABO1108 in adults aged 40 years or above.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-12-03.

Trial Details

NCT Number	NCT07285278
Lead Sponsor	Suzhou Abogen Biosciences Co., Ltd. Collaborators: Abogen Biosciences (Shanghai) Co., Ltd
Conditions	Varicella-zoster Virus
Enrollment	300 participants
Start Date	2025-11-15
Primary Completion	2026-03-09 (estimated)
Study Completion	2027-02-15 (estimated)
Updated on ClinicalTrials.gov	2026-05-11